Journal of Antimicrobial Chemotherapy (2004) 53, ii37-ii50
© 2004 The British Society for Antimicrobial Chemotherapy
Supplement |
Complicated infections of skin and skin structures: when the infection is more than skin deep
1 Merck Research Laboratories, BL 3–4, PO Box 4, West Point, PA 19486, USA; 2 University of Washington School of Medicine and Veterans Administration Puget Sound Health Care System, Seattle, WA, USA
Abstract
Skin and skin-structure infections are common, and range from minor pyodermas to severe necrotizing infections. Complicated infections are defined as involving abnormal skin or wounds, occurring in compromised hosts, or requiring surgical intervention. Classification schemes for these infections are varied and confusing. Distinguishing characteristics include the aetiological agent(s), clinical context and findings, depth of tissue involvement and rate of progression. The most common pathogens are aerobic Gram-positive cocci, but complicated infections frequently involve Gram-negative bacilli and anaerobic bacteria. Initial antibiotic therapy is usually empirical, and later modified by the results of stains and cultures of wound specimens. Broad-spectrum coverage is frequently needed for complicated infections. Ertapenem is a once-a-day parenteral Group 1 carbapenem antibiotic, recently licensed in the USA and Europe, which may assume an important role in treating some complicated skin and skin-structure infections. Surgical debridement is important for many complicated infections, and is the critical element in managing necrotizing fasciitis and myonecrosis.
Keywords: cellulitis, necrotizing fasciitis, myonecrosis, gas gangrene
Footnotes
* Corresponding author. Tel: +1-484-344-3331; Fax: +1-484-344-3404; E-mail: mark_dinubile{at}merck.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. A. B. Copley Pediatric Musculoskeletal Infection: Trends and Antibiotic Recommendations J. Am. Acad. Ortho. Surg., October 1, 2009; 17(10): 618 - 626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-H. Park, S.-I. Jung, Y.-S. Jung, J.-H. Shin, and J.-H. Hwang Marine Bacteria as a Leading Cause of Necrotizing Fasciitis in Coastal Areas of South Korea Am J Trop Med Hyg, April 1, 2009; 80(4): 646 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Amsler, T. A. Davies, W. Shang, M. R. Jacobs, and K. Bush In Vitro Activity of Ceftobiprole against Pathogens from Two Phase 3 Clinical Trials of Complicated Skin and Skin Structure Infections Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3418 - 3423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Florescu, M. Beuran, R. Dimov, A. Razbadauskas, M. Bochan, G. Fichev, G. Dukart, T. Babinchak, C. A. Cooper, E. J. Ellis-Grosse, et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study J. Antimicrob. Chemother., September 1, 2008; 62(suppl_1): i17 - i28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. H. Talbot, D. Thye, A. Das, and Y. Ge Phase 2 Study of Ceftaroline versus Standard Therapy in Treatment of Complicated Skin and Skin Structure Infections Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3612 - 3616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Burkhardt, M. Brunner, S. Schmidt, M. Grant, Y. Tang, and H. Derendorf Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis J. Antimicrob. Chemother., September 1, 2006; 58(3): 632 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Giacometti, O. Cirioni, W. Kamysz, C. Silvestri, M. S. Del Prete, A. Licci, G. D'Amato, J. Lukasiak, and G. Scalise In Vitro Activity and Killing Effect of Citropin 1.1 against Gram-Positive Pathogens Causing Skin and Soft Tissue Infections Antimicrob. Agents Chemother., June 1, 2005; 49(6): 2507 - 2509. [Abstract] [Full Text] [PDF]
|
|